Breaking News
0

Pharma Mar SAU (PMRG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.865 -0.019    -1.01%
02:04:00 - Closed. Currency in EUR ( Disclaimer )
Type: Equity
Market: Germany
ISIN: ES0169501030 
S/N: A1423S
  • Volume: 0
  • Bid/Ask: 1.829 / 1.882
  • Day's Range: 1.865 - 1.865
Pharma Mar 1.865 -0.019 -1.01%

Pharma Mar SA Company Profile

 
Get an in-depth profile of Pharma Mar SAU, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

440

Equity Type

ORD

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.

Contact Information

Phone +34-918-466000
Fax 918-466001

Top Executives

Name Age Since Title
Juan Carlos Villalon Gomez - - Internal Auditor
Ali Zeaiter - 2018 Director of Clinical Development
Alfonso Ortin - 2016 Director of Communications
Belen Sopesen Veramendi - - Director of Market Research and Development
Jose Luis Ortega Conejero - 2004 Director of Quality Unit
Luis Mora Capitan - - Managing Director of Oncology Business Unit
Ana Belen Irigaray Huarte - 2014 Director of Corporate Regulatory Affairs
Elena Calleja Crespo - 2008 Director of Finance - Oncology Business Unit
Pascal M. Besman - - Chief Operating Officer of PharmaMar U.S.
Pedro Berbil Bautista - 2004 Director of Industrial Operations
Jose Luis Moreno Martinez-Losa - - Director of Investor Relations and Capital Markets
Juan Nogues Ortuno - 2013 Director of International Sales and Marketing
Maria Luisa de Francia Caballero - - Chief Financial Officer
Luis Ruperez Cuenca - - Director of Human Resources and IT
Nadia Badri - 2011 Vice President - Medical Affairs
Carmen Cuevas Marchante - 2003 Director of Research & Development
Heiner Pieper - 2013 Vice President - Business Development & Licensing
Sebastian Cuenca Miranda - - General Counsel, Secretary
Jose Maria Fernandez Sousa-Faro - - President, Chief Executive Officer, Executive Chairman of the Board
Pedro Fernandez Puentes - - Executive Vice Chairman
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHMR Comments

Write your thoughts about Pharma Mar SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email